AEGiS-08IAC: Prognostic value of CMV antibodies in persons treated with foscarnet for CMV retinitis.

8th International AIDS Conference


Amsterdam, Netherlands — July 19-24, 1992

Print this Article


Prognostic value of CMV antibodies in persons treated with foscarnet for CMV retinitis.

Int Conf AIDS 1992 Jul 19-24; 8:We54 (abstract no. WeB 1053)
Polis MA, Koenig S, Kramer A, Boppana S, Britt W; NIAID/NIH, Bethesda, MD.

OBJECTIVE: To determine the effect of cytomegalovirus (CMV)-specific antibody levels on the time to retinitis progression in persons with HIV infection who were treated with foscarnet for CMV retinitis.

METHODS: Baseline serum samples for CMV-specific antibodies were blindly assayed in 22 persons with HIV infection and CMV retinitis who were enrolled in a study of foscarnet. Four techniques were used: a commercial ELISA using a mixture of infected cell proteins as an antigen source; immunoprecipitation assays for two different recombinant-derived envelope glycoproteins, gB and gH, and RIA for gB; and neutralizing antibody activity were measured. Progression of retinitis was determined by rigorous photographic endpoints by a masked reading center for 12 patients; progression was determined clinically by an investigator blinded to the results of the antibody assays for the other 10. Patients were then grouped by time to progression and geometric mean antibody titers for the groups were calculated.

RESULTS: Geometric mean CMV antibody levels by group is seen below: TABULAR DATA, SEE ABSTRACT VOLUME.

CONCLUSIONS: Persons with higher levels of neutralizing antibodies tended to have a more prolonged time to progression of retinitis. Studies to address the administration of exogenous antibody with high levels of neutralizing antibody should be explored. This may impact on the treatment of persons with AIDS and CMV retinitis.

Keywords: AEGIS, Foscarnet, Cytomegalovirus Retinitis, Cytomegalovirus, Retinitis, Cytomegalovirus Infections, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Antiviral Agents, Acquired Immunodeficiency Syndrome, HIV Infections, Enzyme-Linked Immunosorbent Assay, MEC protocol 1, Human, ICA8
920719
WeB1053

Copyright © 1992 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.